Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Payables (2016 - 2025)

Rein Therapeutics filings provide 10 years of Payables readings, the most recent being $4.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 336.44% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Dec 2025, up 336.44%, and an annual FY2025 reading of $4.0 million, up 336.44% over the prior year.
  • Payables hit $4.0 million in Q4 2025 for Rein Therapeutics, down from $4.1 million in the prior quarter.
  • The five-year high for Payables was $6.0 million in Q2 2025, with the low at $136000.0 in Q2 2023.
  • Median Payables over the past 5 years was $1.1 million (2021), compared with a mean of $1.6 million.
  • The sharpest move saw Payables tumbled 92.19% in 2023, then surged 670.84% in 2025.
  • Year by year, Payables stood at $1.2 million in 2021, then skyrocketed by 42.15% to $1.7 million in 2022, then plummeted by 30.81% to $1.2 million in 2023, then dropped by 23.45% to $911000.0 in 2024, then skyrocketed by 336.44% to $4.0 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $4.0 million, $4.1 million, and $6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.